The objective of the study is to assess the impact of remote cardiac and vital sign monitoring in patients with coronavirus disease (COVID-19) in the outpatient setting.
The objective of the study is to assess the impact of remote cardiac and vital sign
monitoring in patients with coronavirus disease (COVID-19) in the outpatient setting. This
study will enroll COVID-19 positive patients previously evaluated at Mount Sinai
Hospital/Mount Sinai Health System (MSHS) and affiliated hospitals deemed appropriate for
home monitoring. Patients will be monitored remotely in the outpatient setting for 1-3 weeks
following diagnosis and/or treatment for COVID-19 at MSH/MSHS.
Diagnostic Test: VitalConnect Vital Sign Patch
This patch provides continuous real-time monitoring of cardiac telemetry, heart rate, respiratory rate and oxygen saturation. Duration of monitoring is typically up to 7 days.
This patch is applied to the upper left side of the chest wall, attached with a hypoallergenic adhesive material. (This device is FDA approved for this indication).
- Patients diagnosed with coronavirus and determined to be eligible for home monitoring
and self-care, and either
1. Not admitted to the hospital, and permitted to recover at home
2. Discharged from inpatient hospitalization, during the acute recovery period
- 18 years old or older with the ability to understand the requirements of the study and
sign the informed consent form (or able to provide over-the-phone verbal consent).